Patents by Inventor Peter J. Sims
Peter J. Sims has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080241233Abstract: A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a phospholipid scramblase, has been developed. This platelet substitute provides a means for selectively delivering procoagulant phospholipids and/or fatty acids to the site of vessel injury through targeted adherence to collagen or other component exposed upon vessel injury. These are particularly effective due to the combination of targeting procoagulant vesicles to a site of injury, and triggered exposure of phosphatidylserine (PS) on the surface.Type: ApplicationFiled: March 27, 2008Publication date: October 2, 2008Inventors: Peter J. Sims, Pamela B. Conley, Peng Luan, David R. Phillips
-
Patent number: 7166568Abstract: Compounds modulating CD59 mediated complement activity, compositions including these compounds, and methods of making and using the compounds are disclosed, which are based on the identification of the hu CD59 amino acid residues which serve as the binding site for CD59-C9 interactions. These residues correspond to amino acid residues 42–58, and bind to the region of C9 corresponding to human 334–418, more specifically, between amino acid residues 359 and 384. Compounds can be derived using this basic amino acid sequence and corresponding three dimensional structure within the protein using any of several techniques known to those skilled in the art, including rational drug design using computer data bases and modeling of peptide/protein-ligand binding, antibodies and anti-idiotypic antibodies generated to the proteins or peptides containing this peptide sequence, and modified peptides.Type: GrantFiled: February 9, 1998Date of Patent: January 23, 2007Assignee: Oklahoma Medical Research FoundationInventor: Peter J. Sims
-
Patent number: 6916654Abstract: Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.Type: GrantFiled: May 5, 2000Date of Patent: July 12, 2005Assignees: Oklahoma Medical Research Foundation, Yale UniversityInventors: Peter J. Sims, Alfred L. M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto
-
Publication number: 20030166565Abstract: Compounds modulating CD59 mediated complement activity, compositions including these compounds, and methods of making and using the compounds are disclosed, which are based on the identification of the hu CD59 amino acid residues which serve as the binding site for CD59-C9 interactions. These residues correspond to amino acid residues 42-58, and bind to the region of C9 corresponding to human 334-418, more specifically, between amino acid residues 359 and 384. Compounds can be derived using this basic amino acid sequence and corresponding three dimensional structure within the protein using any of several techniques known to those skilled in the art, including rational drug design using computer data bases and modeling of peptide/protein-ligand binding, antibodies and anti-idiotypic antibodies generated to the proteins or peptides containing this peptide sequence, and modified peptides.Type: ApplicationFiled: March 27, 2003Publication date: September 4, 2003Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventor: Peter J. Sims
-
Publication number: 20030129722Abstract: A protein preparation that mediates Ca+2 transbilayer movement of phospholipid is disclosed. Additionally, a modified or mutated protein preparation, wherein the protein has a reduced ability to mediate transbilayer movement, is disclosed. In a preferred form of the invention, the protein has been modified such that post-translational modification can no longer occur.Type: ApplicationFiled: January 14, 2003Publication date: July 10, 2003Inventors: Therese Wiedmer, Peter J. Sims
-
Patent number: 6534640Abstract: A protein preparation that mediates Ca+2 transbilayer movement of phospholipid is disclosed. Additionally, a modified or mutated protein preparation, wherein the protein has a reduced ability to mediate transbilayer movement, is disclosed. In a preferred form of the invention, the protein has been modified such that post-translational modification can no longer occur.Type: GrantFiled: August 16, 1999Date of Patent: March 18, 2003Assignee: Blood Center Research FoundationInventors: Therese Wiedmer, Peter J. Sims
-
Publication number: 20020137905Abstract: The present invention is based on a family of membrane proteins, Phospholipid Scramblases (PLSCR), that mediate accelerated trans-bilayer movement of plasma membrane phospholipids in response to elevated cytoplasmic calcium. At least one Phospholipid Scramblase gene is highly inducible by interferon. Interferon-induced expression of Phospholipid Scramblase 1 (and/or related genes) alters the physical and functional properties of the cell surface so as to (1) inhibit tumor cell proliferation and survival; (2) inhibit maturation and release of membrane-enveloped viruses; and/or (3) promote clearance of virus-infected cells and cancer cells through the reticuloendothelial system. The present invention provides Phospholipid Scramblase polypeptides, polynucleotide sequences that encode Phospholipid Scramblase polypeptides, and antibodies that are immunoreactive with the polypeptides.Type: ApplicationFiled: March 30, 2001Publication date: September 26, 2002Inventors: Peter J. Sims, Therese Wiedmer, Robert H. Silverman
-
Patent number: 6204035Abstract: A protein preparation that mediates Ca+2 transbilayer movement of phospholipid is disclosed. Additionally, a modified or mutated protein preparation, wherein the protein has a reduced ability to mediate transbilayer movement, is disclosed. In a preferred form of the invention, the protein has been modified such that post-translational modification can no longer occur.Type: GrantFiled: October 10, 1997Date of Patent: March 20, 2001Assignee: The Blood Center Research FoundationInventors: Therese Wiedmer, Peter J. Sims
-
Patent number: 6172210Abstract: An protein preparation that mediates Ca+2 transbilayer movement of phospholipid is disclosed. A recombinantly engineered DNA sequence encoding the protein, an inhibitor of the protein activity, genetically engineered cells with altered protein activity, and therapeutic methods are also disclosed.Type: GrantFiled: January 29, 1997Date of Patent: January 9, 2001Assignee: Blood Center Research FoundationInventors: Therese Wiedmer, Peter J. Sims
-
Patent number: 6100443Abstract: Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.Type: GrantFiled: June 7, 1995Date of Patent: August 8, 2000Assignees: Oklahoma Medical Research Foundation, Yale UniversityInventors: Peter J. Sims, Alfred L. M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto
-
Patent number: 5955441Abstract: A method and means for protecting cells and transplanted organs from the effects of activated complement proteins generated in blood serum or plasma by introducing the gene for CD59 into the cells to be protected is described. In an example of the method, protection against the pore-forming activity of the human C5b-9 proteins was conferred on CHO cells by transfection with cDNA encoding the human complement regulatory protein CD59.Type: GrantFiled: August 13, 1996Date of Patent: September 21, 1999Assignees: Oklahoma Medical Research Foundation, Yale UniversityInventors: Peter J. Sims, Alfred L.M. Bothwell
-
Patent number: 5843884Abstract: Pharmaceutical compositions are designed based on the criticality of a portion of C9 for assembly of the C5b9 complex, which specifically modulate binding of CD59 to C9, either molecules structurally mimicking C9 amino acid residues 359 to 384 which bind to CD59 or molecules binding to C9 amino acid residues 359 to 384. Molecules which inhibit CD59 binding include peptides containing residues 359-384 which compete for binding with the other components of the C5b9 complex and anti-idiotypic antibodies immunoreactive with C9 amino acid residues 359 to 384. Molecules which prevent assembly of the C5b-9 complex include antibodies and antibody fragments immunoreactive with amino acid residues 359 to 384 of C9, peptides that bind to amino acid residues 359 to 384 of C9, and nucleotide molecules that bind to amino acid residues 359 to 384 of C9.Type: GrantFiled: November 15, 1995Date of Patent: December 1, 1998Assignee: Oklahoma Medical Research FoundationInventor: Peter J. Sims
-
Patent number: 5763156Abstract: A composition and methods for use thereof relating to polypeptides having the ability to act as an inhibitor of complement C5b-9 complex activity. The compositions contain an 18 kDa protein found on the surface of human erythrocytes, a 37 kDa protein found on the surface of human platelets, a 37 kDa protein found on the surface of human endothelial cells, active derivatives or fragments thereof which act to inhibit the activity of C5b-9, anti-idiotypic antibodies mimicking the action of the inhibitor proteins or antibodies against C7 or C9 which block the formation of the C5b-9 complex. The compositions can be used in vitro to inhibit C5b-9 related stimulatory responses of platelets and vascular endothelium of perfused organs and tissues, thereby preventing the C5b-9 initiated cell necrosis or stimulated secretion of proteolytic enzymes and the exposure of the procoagulant membrane receptors during collection and in vitro storage.Type: GrantFiled: December 19, 1996Date of Patent: June 9, 1998Assignee: Oklahoma Medical ResearchInventors: Peter J. Sims, Therese Wiedmer
-
Patent number: 5705732Abstract: Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.Type: GrantFiled: July 1, 1993Date of Patent: January 6, 1998Assignees: Oklahoma Medical Research Foundation, Yale UniversityInventors: Peter J. Sims, Alfred L.M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto
-
Patent number: 5660825Abstract: A composition and methods for use thereof relating to polypeptides having the ability to act as an inhibitor of complement C5b-9 complex activity. The compositions contain an 18 kDa protein found on the surface of human erythrocytes, a 37 kDa protein found on the surface of human platelets, a 37 kDa protein found on the surface of human endothelial cells, active derivatives or fragments thereof which act to inhibit the activity of C5b-9, anti-idiotypic antibodies mimicking the action of the inhibitor proteins or antibodies against C7 or C9 which block the formation of the C5b-9 complex. The compositions can be used in vitro to inhibit C5b-9 related stimulatory responses of platelets and vascular endothelium of perfused organs and tissues, thereby preventing the C5b-9 initiated cell necrosis or stimulated secretion of proteolytic enzymes and the exposure of the procoagulant membrane receptors during collection and in vitro storage.Type: GrantFiled: June 5, 1995Date of Patent: August 26, 1997Assignee: Oklahoma Medical Research FoundationInventors: Peter J. Sims, Therese Wiedmer
-
Patent number: 5635178Abstract: Compositions and methods for use thereof relating to monoclonal antibodies, and fragments thereof, having inhibitory activity towards the cell-activating function of the complement C5b-9 complex. The compositions can be used in vitro to inhibit C5b-9 related stimulatory responses of platelets and/or endothelial cells, thereby preventing C5b-9-initiated cell necrosis or stimulated secretion of proteolytic enzymes and the exposure of the procoagulant membrane receptors during collection and in vitro storage. Further, disease states can be treated by administering to platelets and/or endothelial cells in vivo an effective amount of a monoclonal antibody, or fragment thereof, which has inhibitory activity towards the cell-activating function of the C5b-9 complex, in a pharmaceutically acceptable carrier.Type: GrantFiled: March 8, 1994Date of Patent: June 3, 1997Assignee: Oklahoma Medical Research FoundationInventors: Peter J. Sims, Therese Wiedmer
-
Patent number: 5573940Abstract: A method and means for protecting cells and transplanted organs for the effects of activated complement proteins generated in blood serum or plasma by introducing the gene for CD59 into the cells to be protected is described. In an example of the method, protection against the pore-forming activity of the human C5b-9 proteins was conferred on CHO cells by transfection with cDNA encoding the human complement regulatory protein CD59.Type: GrantFiled: July 7, 1994Date of Patent: November 12, 1996Assignees: Oklahoma Medical Research Foundation, Yale UniversityInventors: Peter J. Sims, Alfred L. M. Bothwell
-
Patent number: 5550108Abstract: A composition and methods for use thereof relating to polypeptides having the ability to act as an inhibitor of complement C5b-9 complex activity. The compositions contain an 18 kDa protein found on the surface of human erythrocytes, active derivatives or fragments thereof which act to inhibit the activity of C5b-9, anti-idiotypic antibodies mimicking the action of the inhibitor proteins or antibodies against C7 or C9 which block the formation of the C5b-9 complex. The compositions can be used in vitro to inhibit C5b-9 related stimulatory responses of platelets and vascular endothelium of perfused organs and tissues, thereby preventing the C5b-9 initiated cell necrosis or stimulated secretion of proteolytic enzymes and the exposure of the procoagulant membrane receptors during collection and in vitro storage. Further, immune disease states can be treated by administering an effective amount of a C5b-9 inhibitor to suppress C5b-9 mediated platelet activation in vivo.Type: GrantFiled: May 16, 1994Date of Patent: August 27, 1996Assignee: Oklahoma Medical Research FoundationInventors: Peter J. Sims, Therese Wiedmer
-
Patent number: 5135916Abstract: A composition and methods for use thereof relating to polypeptides having the ability to act as an inhibitor of complement C5b-9 complex activity. The compositions contain an 18 kDa protein found on the surface of human erythrocytes, a 37 kDa proteiThe U.S. Government has rights in this invention by virtue of certain government grants.Type: GrantFiled: June 12, 1989Date of Patent: August 4, 1992Assignee: Oklahoma Medical Research FoundationInventors: Peter J. Sims, Therese Wiedmer